---
title: Reduce unilateral tremor with Exablate
nct_id: NCT04991831
status: RECRUITING
sponsor: InSightec
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04991831"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04991831"
last_fetched: "2026-05-10T14:06:33.616Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce unilateral tremor with Exablate

**Goal (in five words):** Reduce unilateral tremor with Exablate

**Official Title:** A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

**Trial ID:** [NCT04991831](https://clinicaltrials.gov/study/NCT04991831)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** InSightec
- **Target Enrollment:** 50 participants
- **Start Date:** 2022-04-28
- **Completion Date:** 2027-12
- **Conditions:** Tremor Associated With Tremor Dominant Parkinson's Disease
- **Interventions:** Unilateral thalamotomy
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to follow people with tremor-dominant Parkinson's whose tremor does not respond to medications, to see how well a one-sided procedure controls that disabling tremor over time. It uses the Exablate MR-guided focused ultrasound system to heat and destroy a very small area in the motor thalamus on one side of the brain, reducing tremor on the opposite hand without opening the skull. Because the procedure targets the brain circuit that produces tremor, it does not change how levodopa works for other Parkinson's symptoms, though better tremor control may reduce the need for extra tremor medicines. Adults aged 30 to 99 who are already scheduled to receive a unilateral Exablate thalamotomy as part of their usual care and who can sign consent and attend follow-up visits are eligible to join this registry.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 99 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Men and women, age 30 years and older
2. Subject undergoing an Exablate procedure for their planned TDPD treatment; per local institution standard of care.
3. Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all study visits
4. Subject has signed and received a copy of the approved informed consent form

Exclusion Criteria:

Subject does not agree to participate or is unlikely to participate for the entirety of the study.
```

## Locations (8)

- Miami Neuroscience Institute Baptist Health, Miami, Florida, United States _(25.7743, -80.1937)_
  - Justin Sporrer, MD — (CONTACT) — 786-596-2226 — JustinSp@baptisthealth.net
  - Josette Elysée — (CONTACT) — 786-596-1826 — JosetteE@BaptistHealth.net
  - Justin Sporrer, MD — (PRINCIPAL_INVESTIGATOR)
- Rush University, Chicago, Illinois, United States _(41.8500, -87.6500)_
  - Edgar Y Perez — (CONTACT) — 3129427391 — Edgar_Y_Perez@rush.edu
  - Neepa Patel, MD — (PRINCIPAL_INVESTIGATOR)
- Brigham and Women's Hospital, Boston, Massachusetts, United States _(42.3584, -71.0598)_
  - John Rolston, MD, PhD — (CONTACT) — jrolston@bwh.harvard.edu
  - Anna Ball — (CONTACT) — aball@bwh.harvard.edu
  - John Rolston, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Weill Cornell Medicine, New York, New York, United States _(40.7143, -74.0060)_
  - Michael Kaplitt, MD, PhD — (CONTACT) — mik2002@med.cornell.edu
  - Isabella Cipollone — (CONTACT) — 203-917-9918 — isc4005@med.cornell.edu
  - Michael Kaplitt, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Novant Health Brain & Spine Surgery, Huntsville, North Carolina, United States _(36.0824, -80.5295)_
  - Charles Munyon, MD — (CONTACT) — cnmunyon@novanthealth.org
  - Darren Crawford — (CONTACT) — DarrenNCrawford@novanthealth.org
  - Charles Munyon, MD — (PRINCIPAL_INVESTIGATOR)
- Cleveland Clinic Foundation, Cleveland, Ohio, United States _(41.4995, -81.6954)_
  - Courtney Cannon — (CONTACT) — 216-444-1057 — CANNONC2@ccf.org
  - Sean Nagel, MD — (PRINCIPAL_INVESTIGATOR)
- Miami Valley Hospital, Fairborn, Ohio, United States _(39.8209, -84.0194)_
  - Daniel Gaudin, MD — (CONTACT) — 419-481-6220 — dgaudin@premierhealth.com
  - Heather Bell — (CONTACT) — 937-208-6013 — hrbell@premierhealth.com
  - Daniel Gaudin, MD — (PRINCIPAL_INVESTIGATOR)
- University of Dundee, Dundee, Scotland, United Kingdom _(56.4691, -2.9749)_
  - Tom Gilbertson, PhD MBBS — (CONTACT) — t.gilbertson@dundee.ac.uk
  - Kayleigh Anderson — (CONTACT) — Kayleigh.anderson6@nhs.scot
  - Tom Gilbertson, PhD MBBS — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Matt Hibert — (CONTACT) — 214-630-2000 — clinicalresearchquestions@insightec.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT04991831*  
*HTML version: https://parkinsonspathways.com/trial/NCT04991831*  
*Source data: https://clinicaltrials.gov/study/NCT04991831*